MARKET

FATE

FATE

Fate
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.75
+1.81
+7.89%
Opening 11:14 04/06 EDT
OPEN
24.42
PREV CLOSE
22.94
HIGH
25.46
LOW
23.73
VOLUME
536.60K
TURNOVER
--
52 WEEK HIGH
32.39
52 WEEK LOW
12.59
MARKET CAP
1.88B
P/E (TTM)
-17.2366
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FATE stock price target is 38.50 with a high estimate of 63.00 and a low estimate of 28.00.

EPS

FATE News

More
  • Fate Therapeutics (FATE) Looks Good: Stock Adds 8.9% in Session
  • Zacks · 2h ago
  • Growth Investors: Industry Analysts Just Upgraded Their Fate Therapeutics, Inc. (NASDAQ:FATE) Revenue Forecasts By 13%
  • Simply Wall St. · 2d ago
  • Coronavirus Roundtable - Strains And Hopes In The Healthcare Sector
  • Seeking Alpha - Article · 2d ago
  • 7 Promising Biotech Stocks in a Postpandemic World
  • Barrons.com · 2d ago

Industry

Biotechnology & Medical Research
+3.94%
Pharmaceuticals & Medical Research
+3.11%

Hot Stocks

Symbol
Price
%Change

About FATE

Fate Therapeutics, Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its lead clinical program is ProTmune, which is a programmed immuno-regulatory cell therapy. The Company programs immune cells, such as CD34+ cells, Natural Killer (NK) cells and T cells, by utilizing its cell programming approach. Its adoptive cell therapy programs are based on the Company's ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells.
More

Webull offers kinds of Fate Therapeutics Inc stock information, including NASDAQ:FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions.